Windtree Therapeutics
Last usable year: 2024-12-31 — 20 months ago. Nothing filed since gives the figures a payout ratio needs. For a company that once paid, that usually means it stopped.
| Basis | Payout | Why |
|---|---|---|
| GAAP earnings | negative | whyLost $104.35 per share — no earnings to pay from. |
| Operating cash flow | negative | whyOperations consumed $15.4m of cash. |
| Free cash flow | negative | whyOCF fell $15.4m short of capex — the dividend was not funded from free cash flow. |
Nothing is marked as applying, deliberately — no basis produces a ratio. Earnings, operating cash flow and free cash flow are all negative, so there is no denominator to divide the dividend by. That is not a gap in the data; it is the answer. The dividend was funded from something other than the money the business made this year — borrowing, cash on hand, or asset sales — and the filing will say which.
The arithmetic
- GAAP earnings — dividends declared per share $0.0125 ÷ diluted EPS $-104.35
- Operating cash flow — dividends paid $657k ÷ operating cash flow $-15.4m
- Free cash flow — dividends paid $657k ÷ (operating cash flow $-15.4m − capex $12k)
Where the figures came from
- 10-K filed 2025-04-15 · accession 0001437749-25-012093
Every one is public at sec.gov and free to check. That is the point — you should not have to take our word for any of it.
Caveats on this company
- DPS derived from dividends paid ($0.01); no per-share tag filed
Computed by an open pipeline reading SEC XBRL directly. If any number here looks wrong to you, tell us — that is more useful to us than agreement.
Who else looks like this
Every figure above is computed from Windtree Therapeutics’s own filing, and every company here is measured the same way. Screen all of them on any of these twelve measures, or on the rules two investors published — free, and nothing you screen leaves your browser.